<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939441</url>
  </required_header>
  <id_info>
    <org_study_id>IN-CN-320-5613</org_study_id>
    <nct_id>NCT04939441</nct_id>
  </id_info>
  <brief_title>Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)</brief_title>
  <official_title>Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jidong Jia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ShuGuang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Third Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Sixth Peoples Hospital of Zhengzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with&#xD;
      chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver&#xD;
      fibrosis is still unknown. Here, we enrolled treatment naive CHB patients with biopsy-proven&#xD;
      significant fibrosis (METAVIR fibrosis stage ≥ F2). All enrolled subjects will be treated&#xD;
      with TAF monotherapy for 96 weeks. After 96 weeks of therapy, the second liver biopsy will be&#xD;
      performed to evaluate the rate of liver fibrosis regression. During this study, all subjects&#xD;
      will be assessed for laboratory tests, imaging examination at baseline, first 12-week and&#xD;
      every 24-week during follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects will be treated for 96 weeks with TAF [Vemlidy® 25mg QD] monotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with fibrosis regression</measure>
    <time_frame>Week 96</time_frame>
    <description>Fibrosis stage decrease at least 1 point by Ishak score or &quot;Predominantly Regressive&quot; by &quot;Beijing classification&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HBV DNA undetectable rate</measure>
    <time_frame>Week 96</time_frame>
    <description>Serum HBV DNA &lt;20 IU/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of liver stiffness decrease &gt;= 30%</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>Proportion of patients with liver stiffness decrease &gt;= 30% from baseline to week 48 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA undetectable rate</measure>
    <time_frame>Week 24, Week 48 and Week 72</time_frame>
    <description>HBV DNA undetectable rate at week 24, 48, and 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization rate</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>Proportion of patients with ALT &lt;= 1.0xULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg and HBsAg loss and seroconversion rate</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>Proportions of patients with HBsAg loss and seroconversion to anti-HBs, and proportions of patients with HBeAg loss and seroconversion to anti-HBe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in renal function</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>Changes of eGFR (estimated Glomerular Filtration rate) from baseline to week 48 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of bone mineral density</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>Percentage changes in spine BMD and hip BMD from baseline to week 48 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of liver-related endpoint events</measure>
    <time_frame>Week 96</time_frame>
    <description>liver-related endpoint events: decompensation, HCC, liver transplantation, liver-related death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>TAF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAF [Vemlidy® 25mg QD] monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide</intervention_name>
    <description>Subjects will be treated for 96 weeks with TAF [Vemlidy® 25mg QD] monotherapy</description>
    <arm_group_label>TAF group</arm_group_label>
    <other_name>Vemlidy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-69 years old (inclusive);&#xD;
&#xD;
          -  BMI (18-30 kg/m2);&#xD;
&#xD;
          -  Chronic hepatitis B virus (HBV) infection, defined as positive serum hepatitis B&#xD;
             s-antigen (HBsAg) for more than 6 months; or chronic hepatitis B proven by live&#xD;
             biopsy;&#xD;
&#xD;
          -  Not received nucleoside (acid) analogue and/or interferon therapy (treatment-naive);&#xD;
&#xD;
          -  Liver biopsy performed within 6 months before treatment and had readable biopsy slides&#xD;
             or agrees to have a biopsy performed prior to baseline;&#xD;
&#xD;
          -  METAVIR fibrosis stage ≥ F2;&#xD;
&#xD;
          -  For patients without cirrhosis (F2/3), HBV DNA levels &gt;2000 IU/mL before treatment;&#xD;
             For patients with cirrhosis (F4), HBV DNA &gt;20 IU/mL before treatment;&#xD;
&#xD;
          -  ALT≤10 ULN before treatment;&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min;&#xD;
&#xD;
          -  Agreement not to undertake other HBV systemic antiviral or interferon (IFN) regimens&#xD;
             during participation in this study;&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Child-Turcotte-Pugh（CTP）score ≥ 7;&#xD;
&#xD;
          -  Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy,&#xD;
             esophageal varices bleeding or other complications of decompensated cirrhosis or liver&#xD;
             transplantation;&#xD;
&#xD;
          -  Patients co-infection with hepatitis C virus (HCV), human immunodeficiency virus&#xD;
             (HIV), or hepatitis delta virus (HDV), or alcoholic liver diseases, autoimmune liver&#xD;
             disease, genetic liver disease, drug-induced liver injury, non-alcoholic fatty liver&#xD;
             disease or other chronic liver diseases;&#xD;
&#xD;
          -  Patients with evidence of hepatocellular carcinoma (HCC) by imaging with or without&#xD;
             AFP;&#xD;
&#xD;
          -  Patients with other uncured malignant tumors;&#xD;
&#xD;
          -  Patients with organ or bone marrow transplantation;&#xD;
&#xD;
          -  Patients currently receiving therapy with immunomodulators (eg, corticosteroids,&#xD;
             etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying&#xD;
             renal excretion;&#xD;
&#xD;
          -  Patients who are allergic to any component of TAF;&#xD;
&#xD;
          -  Patients who recently or newly started bisphosphate (within 1 month);&#xD;
&#xD;
          -  Patients with active alcohol or drug abuse or history of alcohol or drug abuse (hinder&#xD;
             compliance with treatment, or participation in the study or interpretation of results&#xD;
             considered by the Investigator);&#xD;
&#xD;
          -  Patients with significant renal, cardiovascular, pulmonary, or neurological disease&#xD;
&#xD;
          -  Males and females of reproductive potential who are unwilling to use an effective&#xD;
             method of contraception during the study;&#xD;
&#xD;
          -  Pregnant women, women who are breast feeding or who believe they may wish to become&#xD;
             pregnant during the course of the study;&#xD;
&#xD;
          -  Not suitable for this study identified by researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jidong Jia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital, Capital Medical Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jidong Jia</last_name>
    <phone>86-010-63139246</phone>
    <email>jia_jd@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jialing Zhou</last_name>
    <phone>86-010-63138665</phone>
    <email>zhoujialing11@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Xie</last_name>
      <email>xiewen6218@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shuguang Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenghai Liu</last_name>
      <email>chenghailiu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiming Zhang</last_name>
      <phone>13816317838</phone>
      <email>jmzhang@fudan.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Xie</last_name>
      <phone>13651804273</phone>
      <email>xieqingrjh@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingyi Xu</last_name>
      <email>xumingyi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300170</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Han</last_name>
      <email>hantaomd@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Second People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li</last_name>
      <phone>13920265719</phone>
      <email>tjlplxg@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K; GS-US-320-0110 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195. doi: 10.1016/S2468-1253(16)30024-3. Epub 2016 Sep 22. Erratum in: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):e2.</citation>
    <PMID>28404091</PMID>
  </results_reference>
  <results_reference>
    <citation>Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22. Erratum in: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):e2.</citation>
    <PMID>28404092</PMID>
  </results_reference>
  <results_reference>
    <citation>Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17.</citation>
    <PMID>29756595</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Jidong Jia</investigator_full_name>
    <investigator_title>Director of Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>Liver fibrosis, Liver cirrhosis</keyword>
  <keyword>Tenofovir alafenamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

